As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.
The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...
Annual Meeting featured a poster presentation by Dr. Akihiro Kumono and colleagues from Tokyo Women’s Medical University ...
Soputro delivered a podium presentation comparing outcomes between transvesical (TV) and extraperitoneal (EP) approaches for single-port robotic-assisted radical prostatectomy (SP-RARP). As ...
At the morning plenary session on the final day of the 2026 American Urological Association Annual Meeting, Nima Nassiri presented the groundbreaking world’s first human bladder transplantation, ...
These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, which supports broader ...
Lenherr SM. State-of-the-Art Lecture: New Developments in Urinary Catheters. Presented at: 2026 American Urological ...
These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.
ImmunityBio to serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address ...
Liao delivered a state-of-the-art lecture on Computer Vision in Endourology, highlighting how artificial intelligence (AI) ...
Also previously reported, there was no benefit for extended pelvic lymphadenectomy in the overall cohort for metastasis free ...
Chan of Marin Health UCSF Health Clinic, in collaboration with Dr. Kymora Scotland and colleagues from UCLA, presented a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results